Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ontak in Fludarabine-Refractory B-Cell CLL
NCT00082940Phase 2Completed
- Sponsor
- Wake Forest University Health Sciences
- Start
- Aug 2002
- Primary completion
- Jan 2005
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of denileukin diftitox in chronic lymphocytic leukemia (CLL), sponsored by Wake Forest University Health Sciences. Primary endpoint: Objective Response Rate. Started Aug 2002; status: completed.
02
Drugs
denileukin diftitox
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT00082940.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00082940.